Phase 3 N=903 Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)
Traumatic Hemorrhage
Primary: 30 Day Mortality — 36; 45 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=750 Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain
Postoperative Delirium · Postoperative Pain · Opioid Use
Primary: Incidence of Postoperative Delirium by Study Group — 84; 72 Participants
Phase 3 N=40 FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump
Type 1 Diabetes Mellitus
Primary: 1-Hour Change in Postprandial Plasma Glucose (PPG) — 105.15; 154.24; 99.90; 114.94 mg/dL — p=.008
Phase 3 N=91 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Chronic Spontaneous Urticaria · Angioedema
Primary: Mean Change From Baseline Using Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Total Scores During the Study: Unadjusted Analysis and ANCOVA (LOCF) (FAS)…
Phase 3 N=285 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10 — 26.45; 20.31 Percentage of subjects — p=0.229
Phase 3 N=156 18F-AV-1451 Autopsy Study
Alzheimer's Disease
Primary: Primary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score) — 97.4; 68.0; 92.3; 92.0 percentage of cases correctly identified
Phase 3 N=552 Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score — -22.90; -23.28; -22.64; -24.37 score on a scale — p=0.8035
Phase 3 N=167 Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs) — 133 Participants
Phase 3 N=373 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale — -3.10; -3.49; -2.80 units on a scale
Phase 3 N=117 Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
Chronic HCV Infection
Primary: Evaluation of the Efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve as Measured by the Proportion of Subjects With Sustained…
Phase 3 N=46 Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis
Aggressive Periodontitis
Primary: Change in Clinical Attachment Level (CAL) — 3.69; 3.62; 2.4; 3 mm
Phase 3 N=462 Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
Actinic Keratoses
Primary: Percentage of Subjects in Each Treatment Group With Complete Clearance of AK Lesions at the Test of Cure Visit (Week 24) — 74; 72; 7 Participants — p=0.0001
Phase 3 N=45 Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis
Primary Haemophagocytic Lymphohistiocytosis
Primary: Overall Response Rate (ORR) Second Line — 63.0 percentage of participants — p=0.0134
Phase 3 N=420 A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
Dry Eye Syndrome
Primary: Mean Ocular Surface Disease Index (OSDI) Total Score — 35.0; 40.3; 36.9 score on a scale
Phase 3 N=80 Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty
Total Hip Arthroplasty
Primary: Pain Scores Using Visual Analog Scale (VAS) Scores — 2.34; 3.33 units on a scale